This week, apixaban edges out other DOACs for octogenarians, methotrexate fails to cut cardiovascular events in a large trial,
withdrawing heart failure medications after recovery leads to relapse,
and showing patients their own atherosclerosis may reduce their cardiovascular event risk.
